Research programme: benzopyran-based therapeutics - Novogen/Genea Biocells

Drug Profile

Research programme: benzopyran-based therapeutics - Novogen/Genea Biocells

Alternative Names: Super-benzopyran compounds - Novogen/Genea

Latest Information Update: 26 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genea Biocells; Novogen
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Electron transport chain complex protein inhibitors; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Brain disorders; Brain injuries; Facioscapulohumeral muscular dystrophy; Mucopolysaccharidosis III

Most Recent Events

  • 02 May 2014 Novogen and Genea agree to co-develop benzopyran-based degenerative disorder therapeutics for degenerative disorders, including neuroaxonal dystrophy, facioscapulohumeral muscular dystrophies, amyotrophic lateral sclerosis, mucopolysaccharidosis III and Alzheimer's disease
  • 02 May 2014 Preclinical trials in Alzheimer's disease in Australia (Parenteral)
  • 02 May 2014 Preclinical trials in Amyotrophic lateral sclerosis in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top